MOLECULAR EXPRESS, INC — Department of Health and Human Services SBIR Phase I: NIAID

Description

Project Summary The current standard of care for peanut allergy is strict avoidance of peanuts Due to the contamination of various food items with peanut protein allergens complete avoidance is difficult to achieve and reduces the quality of life in allergic individuals for fear of accidental ingestion Upon accidental exposure allergic individuals must quickly self administer or receive epinephrine injections and antihistamines to prevent the symptoms associated with the onset of an allergic reaction To treat peanut allergies a more recent strategy being tested is allergen specific immunotherapy which focuses on preventing the development of allergic symptoms by altering the pathologic immune response to non pathogenic antigens and inducing clinical desensitization which is defined as an increase in the threshold of ingested allergen needed to cause allergic symptoms Clinical trials investigating long term oral and sublingual delivery of escalating low doses of peanut proteins as a form of allergen specific immunotherapy have been conducted and achieved some success at inducing clinical peanut desensitization in peanut allergic individuals The effectiveness of oral immunotherapy has been demonstrated by the ability of peanut allergic patients treated with active oral immunotherapy to tolerate mg of peanuts whereas placebo treated patients were only able to tolerate mg of peanuts However the daily administration schedule and duration of treatment andgt year as well as the occurrence of mild adverse effects such as itching and sneezing and on rare occasions severe respiratory reactions are some of the shortcomings of current peanut specific mucosal immunotherapy In addition although desensitization can be achieved by mucosal immunotherapy long term tolerance has yet to be demonstrated as half of the patients who are successfully desensitized regain sensitization after weeks of allergen withdrawal In summary the length of time required to achieve clinical desensitization the potential of experiencing adverse effects associated with peanut specific mucosal immunotherapy and the short duration of the desensitization of the immune response profile while providing evidence that allergen specific immunotherapy can work suggests that there is still room for improvement by the implementation of novel therapies that reduce the time to desensitization and the possibility of adverse reactions One strategy for improving current peanut immunotherapy protocols would be to design an immunotherapy formulation that rapidly induces long lasting peanut specific Th and T regulatory responses while minimizing adverse effects in a hypersensitive host Sensitization to peanut allergens occurs by the induction of peanut specific T helper Th type cells that secrete Interleukin IL and to support B cell production of peanut specific IgE that binds mast cells MC and basophils The major peanut allergen proteins are Ara h and It is estimated that of peanut allergic individuals have IgE specific for Ara h and and of peanut hypersensitive people have Ara h specific IgE Exposure to peanut in allergic hosts crosslinks surface IgE on mast cells and basophils inducing their degranulation and secretion of inflammatory mediators that produce allergy symptoms A recent publication described the ability of injection immunotherapy with peanut extract PN adjuvanted with the Toll like Receptor TLR agonist CpG to reduce allergic disease severity in mice Since injection therapy is impractical due to the incidence of severe adverse reactions mucosal delivery of immunotherapy formulations would be much more acceptable for clinical development The Staats laboratory at Duke University has recently developed a mouse model of nasal immunotherapy against peanut allergies and shown that a combination of PN adjuvanted with CpG in this mucosal immunization model facilitated a reduction in the severity of peanut induced anaphylaxis in hypersensitive mice in a manner that is superior to therapy with PN alone In this SBIR Phase I application we propose to demonstrate that VesiVax liposome formulations containing immunostimulatory adjuvant molecules that have been shown to stimulate cellular immune responses can be used to re direct the response of the immune system to an allergen into a non allergic response profile We will focus on peanut allergens to demonstrate the proof of concept that VesiVax liposomes can facilitate the switching of the immune response to a non allergenic response pattern We will collaborate with Professor Staats laboratory to conduct these studies Public Health Relevance Food allergy is a type one immediate onset hypersensitivity that is responsible for cases of anaphylaxis and deaths each year in the United States alone Although it is possible to induce allergic responses to any dietary protein the majority of allergic food reactions are a result of the following eight sources cow s milk eggs wheat soy shellfish fish tree nuts and peanuts Peanuts and tree nuts account for of severe allergic food reactions and it is projected that over million Americans have an allergy to peanuts and will maintain this allergy throughout their lifetime It is estimated that of children in the Westernized world are allergic to peanuts Unlike milk or egg allergies peanut hypersensitivity is rarely outgrown and the majority of fatal and near fatal reactions to foods are caused by peanuts and tree nuts In addition peanut allergens have been shown to cross react with other nut allergens and present additional hypersensitivities Trace amounts of peanut can be found in many dietary products and can trigger severe reactions Thus patients that suffer from peanut allergy often experience a decreased quality of life for fear of accidental ingestion Since there are no approved therapies to cure peanut allergies the development of novel effective therapeutic strategies that reduce the incidence of allergic reactions and improve the quality of life of peanut allergic individuals would have a significant impact on public health